Cannabis Science Inc. Cannabis Science Inc.
Cannabis Science Inc. Cannabis Science Inc.
  • Home
  • About Us
    • Corporate Overview
    • Mission Statement
    • Cannabis Science Team
    • Careers & Corporate Culture
  • iCannabinoid
    • Join Now!
  • R&D
    • The Science of Cannabinoids
    • CBIS Cannabinoid Research
    • Critical Ailments
  • COLLABORATIONS & PROJECTS
    • CBIS Medical Consortium
    • Global Economic Development
    • Pan African A & C University
    •     African Economic Initiative
    • American States University
    •     North American Economic Initiative
    • Dana-Farber
    • CFA
    • Stellenbosch University
    • CBIS Bottle It
  • Products & Pharmacies
    • Products
    • Order Online
    • Pharmacies
  • Investors
    • CBIS Current Share Structure
    • SEC Filings
  • Media
    • CBIS News Releases
    • CBIS In The News
    • CBIS Events
  • Contact

latest Articles

  • Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth
  • Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements
  • Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions
  • Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally
  • Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations

  1. Home

Total: 448 results found.

Page 1 of 23

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth

Created on 2019-10-21 23:39:00

Cannabis Science Enters Transition Stage as Trading of the Company’s Shares is Halted; The Company Will Continue to Implement Its Growth Strategy and Resolve All Outstanding Fully Reporting Requirements

Created on 2019-09-06 10:37:00

Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS CDN Economic Development Plan; CBIS to Use Its Relations With the Harvard International Phytomedicines and Medical Cannabis Institute and Other Leading Institutions

Created on 2019-08-28 10:37:00

Cannabis Science Prepares Announcements for Revenues and Corporate Growth; Finalizing New Asset Partnerships and Acquisitions Targeting Positive Cash Flow in Key Markets Globally

Created on 2019-08-15 10:37:00

Cannabis Science Successfully Completes European Headquarters and Operations Move to The Netherlands and Completes Shut Down of All Cannabis Science Europe GmbH Germany Operations

Created on 2019-08-05 10:37:00

Cannabis Science, Inc. Successfully Completes Lab Testing for Its Proprietary, Short-Time Vacuum Distillation Process for Distribution of Purified High CBDA and CBD Water-Soluble Powders and Extracts Internationally

Created on 2019-07-26 10:37:00

Mr. Raymond C. Dabney Prepares Cannabis Science for the Next Level With Key Acquisitions Negotiated and Planned Mergers, a New Branding Splash, and a Black-Tie Dinner Awards Gala for the Ages

Created on 2019-07-08 10:37:00

Cannabis Science Propels Cancer Clinical Trials, Appoints Cellular Cancer Specialist Dr. Sulma Mohammed, Professor of Cancer Biology, Purdue University, to the Company’s Scientific Advisory Board

Created on 2019-06-03 10:37:00

GHC Summit at Harvard Medical School Announces Cannabis Science as Industry Partner in the Launch of the International Phytomedicines Institute at Harvard Medical Schoo

Created on 2019-05-31 10:37:00

Cannabis Science Set to Participate in the Premier Event Focused on High-Impact Global Collaborations; The Global Health Catalyst Summit at Harvard Medical School Starts Today

Created on 2019-05-24 10:37:00

Cannabis Science Announces NFL Greats Past and Present Set to Participate and Partner With the Global Health Catalyst Summit at Harvard Medical School on May 24-26, 2019

Created on 2019-05-23 10:37:00

Cannabis Science and Dana-Farber Cancer Institute Sign a New Research Agreement to Investigate Proprietary Extract From Justicia Plant

Created on 2019-05-20 10:37:00

Sulma Mohammed

Created on 2019-05-16 23:10:07

Cannabis Science Releases Clinical Drug-Development Pipeline as it Transitions Into Clinical Trials; Right on Time for the Upcoming Global Health Catalyst Summit at Harvard Medical School, May 24-26, 2019

Created on 2019-05-10 10:37:00

OVER THE COUNTER

Created on 2019-05-09 23:17:14

STATE BY STATE

Created on 2019-05-09 23:17:14

CLINICAL DRUG DEVELOPMENT

Created on 2019-05-09 23:17:14

CBIS Product Pipeline

Created on 2019-05-09 23:17:14

Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN) Initiated as Cannabis Science Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products Utilizing the Company’s Patent

Created on 2019-04-15 10:37:00

Elpasso Farms Just Announced South African Health Products Regulatory Authority (SAHPRA) Awarded Elpasso Farms One of the First Medical Cannabis Cultivation Licenses; Cannabis Science Applauds

Created on 2019-04-10 10:37:00

  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
REACH US.

2019 US Federal Contractor

DUNS number: 830406356
CAGE code: 5FZM9

NAICS Codes selected:

541711 - Research and Development in Biotechnology

621511 - Medical Laboratories

624230 - Emergency And Other Relief Services

Contact.

Cannabis Science Inc.

Mr. Raymond C. Dabney
President & CEO

raymond.dabney@cannabisscience.com



 
 
Copyright © 2019 Cannabis Science Inc. All Rights Reserved.